EFFECTIVENESS OF SINGLE DOSE INTRAVESICAL MITOMYCIN C THERAPY AS PROPHYLAXIS TO PREVENT RECURRENCE AND PROGRESSION OF SUPERFICIAL NONMUSCLE INVASIVE BLADDER TUMOR

• Published in: The professional medical journal Vol. 26; no. 7; pp. 1116 - 1120
• Main Authors: Saulat, Sherjeel, Soomro, Anees Ur Rehman, Azad, Muhammad Murtaza
• Format: Journal Article
• Language: English
• Published: 10-07-2019
• ISSN: 1024-8919; 2071-7733
• DOI: 10.29309/TPMJ/2019.26.07.3778

Objectives: To determine the effectiveness of instillation of single dose of intravesical mitomycin C in patients with low grade non-muscle invasive bladder tumor (NMIBT). Study Design: Retrospective cross-sectional study. Setting: Tabba kidney institute Karachi. Period: 2016 to Jan-2018. Subject and Methods: A total of 76 patients with first time diagnosis of non-invasive bladder tumor were included. Data of patients of SNMIBT who underwent trans-uretheral resection of bladder tumor (TURBT) and received single dose instillation of mitomycin C (MMC, 40 mg) within 24 hours after resection from 2016 to Jan-2018 were included in this analysis. All these patients were followed for 6 months after TURBT, cystoscopy was performed at 3 and 6 monthly to check and record any recurrence or progression. Results: Out of 76 cases, 43 (56.57%) had one lesion, 27 (35.52%) had two lesion and 6 (7.89%) cases had three lesion. Single dose intravesical mitomycin C was effective in 81.57% (62/76) cases, recurrence occurred in 6 (7.89 %) cases and progression of disease in 8 (10.52%) cases. Conclusion: The results of present study confirmed the positive effect of instillation of single immediate dose of MMC in patients with low risk superficial bladder tumor. 81.57% patients will not require any further treatment if MMC-40 is given immediately following TURBT.